StockNews.com Upgrades InfuSystem (NYSEAMERICAN:INFU) to Strong-Buy

InfuSystem (NYSEAMERICAN:INFU) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Thursday.

InfuSystem Trading Up 1.3 %

Shares of INFU opened at $8.06 on Thursday. The firm has a market capitalization of $170.71 million, a price-to-earnings ratio of 268.76 and a beta of 1.24. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.66 and a current ratio of 2.08. InfuSystem has a 52 week low of $7.87 and a 52 week high of $11.44.

Institutional Trading of InfuSystem

Several hedge funds have recently added to or reduced their stakes in INFU. Vanguard Group Inc. increased its position in shares of InfuSystem by 2.3% in the fourth quarter. Vanguard Group Inc. now owns 1,065,298 shares of the medical instruments supplier’s stock valued at $11,228,000 after acquiring an additional 23,976 shares during the last quarter. BlackRock Inc. grew its holdings in InfuSystem by 597.8% during the second quarter. BlackRock Inc. now owns 1,029,364 shares of the medical instruments supplier’s stock worth $9,913,000 after purchasing an additional 881,856 shares during the period. Punch & Associates Investment Management Inc. grew its holdings in InfuSystem by 3.2% during the third quarter. Punch & Associates Investment Management Inc. now owns 939,918 shares of the medical instruments supplier’s stock worth $9,061,000 after purchasing an additional 28,807 shares during the period. Meros Investment Management LP grew its holdings in InfuSystem by 0.4% during the fourth quarter. Meros Investment Management LP now owns 884,090 shares of the medical instruments supplier’s stock worth $9,318,000 after purchasing an additional 3,709 shares during the period. Finally, Wasatch Advisors Inc. grew its holdings in InfuSystem by 18.6% during the first quarter. Wasatch Advisors Inc. now owns 859,679 shares of the medical instruments supplier’s stock worth $8,425,000 after purchasing an additional 135,076 shares during the period. Institutional investors and hedge funds own 71.13% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.